Have a feature idea you'd love to see implemented?
Let us know!
MGX Metagenomi Inc.
Price (delayed)
$1.82
Market cap
$68.11M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$7.66
Enterprise value
$83.82M
We are a precision genetic medicines company committed to developing curative therapeutics for patients using our proprietary, comprehensive metagenomics-derived genome editing toolbox. Genetic diseases are caused by a diverse set
Highlights
Metagenomi's EPS has soared by 59% YoY and by 41% from the previous quarter
The company's gross profit rose by 45% YoY
The net income has declined by 16% year-on-year
The equity has declined by 5% since the previous quarter
Key stats
What are the main financial stats of MGX
Market
Valuations
Earnings
Shares outstanding
37.42M
Market cap
$68.11M
Enterprise value
$83.82M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.27
Price to sales (P/S)
1.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.52
Revenue
$55.08M
EBIT
-$75.53M
EBITDA
-$65.85M
Free cash flow
-$107.91M
Per share
Balance sheet
Liquidity
EPS
-$7.66
Free cash flow per share
-$2.93
Book value per share
$6.83
Revenue per share
$1.5
TBVPS
$9.75
Total assets
$358.35M
Total liabilities
$102.58M
Debt
$46.07M
Equity
$255.77M
Working capital
$236.6M
Debt to equity
0.18
Current ratio
6.18
Quick ratio
6.14
Net debt/EBITDA
-0.24
Margins
Efficiency
Dividend
EBITDA margin
-119.6%
Gross margin
100%
Net margin
-134.3%
Operating margin
-160.6%
Return on assets
-19.4%
Return on equity
-44.5%
Return on invested capital
-26.8%
Return on capital employed
-24.2%
Return on sales
-137.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MGX stock price
How has the Metagenomi stock price performed over time
Intraday
10.3%
1 week
-3.19%
1 month
-5.21%
1 year
N/A
YTD
N/A
QTD
-16.13%
Financial performance
How have Metagenomi's revenue and profit performed over time
Revenue
$55.08M
Gross profit
$55.08M
Operating income
-$88.47M
Net income
-$73.95M
Gross margin
100%
Net margin
-134.3%
The company's gross profit rose by 45% YoY
The revenue is up by 45% year-on-year
The net margin has increased by 20% year-on-year
Metagenomi's operating income has decreased by 19% YoY
Growth
What is Metagenomi's growth rate over time
Valuation
What is Metagenomi stock price valuation
P/E
N/A
P/B
0.27
P/S
1.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.52
Metagenomi's EPS has soared by 59% YoY and by 41% from the previous quarter
The equity has declined by 5% since the previous quarter
The revenue is up by 45% year-on-year
Efficiency
How efficient is Metagenomi business performance
Metagenomi's ROE has soared by 57% from the previous quarter
The ROIC has contracted by 21% YoY but it has grown by 3.2% from the previous quarter
MGX's ROA is down by 18% YoY
Metagenomi's ROS has increased by 9% YoY but it has decreased by 4.7% from the previous quarter
Dividends
What is MGX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MGX.
Financial health
How did Metagenomi financials performed over time
MGX's current ratio is up by 42% year-on-year and by 6% since the previous quarter
MGX's quick ratio is up by 40% year-on-year and by 6% since the previous quarter
The debt is 82% smaller than the equity
The company's debt to equity has surged by 144% YoY
The equity has declined by 5% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.